Emerging from stealth mode, Aardvark rounds up enough cash to put its lead drug through Prader-Willi PhII

Josh Sullivan

When Aardvark Therapeutics CEO Tien Lee started his work on the biotech’s lead candidate, appetite suppression was the goal for the small molecule. Soon after …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Emerging from stealth mode, Aardvark rounds up enough cash to put its lead drug through Prader-Willi PhII

Josh Sullivan

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Emerg­ing from stealth mode, Aard­vark rounds up enough cash to put its lead drug through Prad­er-Willi PhII

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Emerging from stealth mode, Aardvark rounds up enough cash to put its lead drug through Prader-Willi PhII